Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 26;100(5):302-309.
doi: 10.1136/sextrans-2024-056150.

Synergistic interaction between pay-it-forward incentives and recreational drug use on hepatitis B virus and hepatitis C virus testing among men who have sex with men in China

Wei Ai  1   2 , Yewei Xie  2 , Haidong Lu  3 , Ting Ai  4 , Dan Wu  5 , Ye Zhang  5 , Gifty Marley  2 , Jason Ong  6 , Joseph D Tucker  2   7 , Weiming Tang  8   2
Affiliations

Synergistic interaction between pay-it-forward incentives and recreational drug use on hepatitis B virus and hepatitis C virus testing among men who have sex with men in China

Wei Ai et al. Sex Transm Infect. .

Abstract

Objectives: Pay-it-forward incentives effectively promote hepatitis B virus (HBV) and hepatitis C virus (HCV) testing among men who have sex with men (MSM) by offering free testing and donation opportunities. This study aims to explore the interaction between pay-it-forward incentives and recreational drug use on HBV and HCV testing uptake among Chinese MSM.

Methods: We pooled data from two pay-it-forward studies that aimed to promote dual HBV and HCV testing among MSM in Jiangsu, China. We explored factors associated with hepatitis testing uptake in the two study groups and examined the interaction between pay-it-forward incentives and recreational drug use on hepatitis testing uptake.

Results: Overall, 511 MSM participated in these two studies, with 265 participants in the pay-it-forward incentives group and 246 participants in the standard-of-care group. Among these participants, 59.3% in the pay-it-forward incentive group and 24.8% in the standard-of-care group received dual HBV and HCV testing, respectively. In the pay-it-forward incentives group, participants who used recreational drugs in the past 12 months (adjusted OR (AOR)=1.83, 95% CI 1.09 to 3.06) were more likely to receive dual HBV and HCV testing, compared with those who never used recreational drugs, whereas in the standard-of-care group, those who used recreational drugs were less likely to receive dual HBC and HCV testing (AOR=0.38, 95% CI 0.18 to 0.78). MSM with higher community connectedness (AOR=1.10, 95% CI 1.00 to 1.21) were also more likely to receive hepatitis testing with pay-it-forward incentives. There was a synergistic interaction on both the multiplicative (ratio of ORs=4.83, 95% CI 1.98 to 11.7) and additive scales (the relative excess risk of interaction=2.97, 95% CI 0.56 to 5.38) of pay-it-forward incentives and recreational drug use behaviours on dual HBV and HCV testing uptake among MSM.

Conclusion: Pay-it-forward incentives may be particularly useful in promoting hepatitis testing among MSM who use recreational drugs.

Keywords: Behavioral Sciences; HEPATITIS; HEPATITIS B; HEPATITIS C; Homosexuality, Male.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Similar articles

See all similar articles

References

    1. World Health Organization. Combating hepatitis B and C to reach elimination by 2030: advocacy brief. 2016. https://www.who.int/publications/i/item/combating-hepatitis-b-and-c-to-r... (accessed 4 November 2023).
    1. Cui F, Blach S, Manzengo Mingiedi C, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol 2023; 8(4): 332–342. - PubMed
    1. Zhang L, Liu H, Zou Z, et al. Shared-care models are highly effective and cost-effective for managing chronic hepatitis B in China: reinterpreting the primary care and specialty divide. Lancet Reg Health West Pac 2023; 35: 100737. - PMC - PubMed
    1. Fang K, Wang HL, Lin Y, Li S, Wu J. Modeling the Impacts of Prevention and Treatment Interventions on Hepatitis C Among People Who Inject Drugs in China. Infect Dis Ther 2023; 12(4): 1043–1055. - PMC - PubMed
    1. Wong WCW, Marley G, Li J, et al. A randomized controlled trial enhancing viral hepatitis testing in primary care via digital crowdsourced intervention. NPJ Digit Med 2022; 5(1): 95. - PMC - PubMed

Publication types